AimRNA

Novel Biologic RNA Therapeutics

Aiming Yu, Founder & President
yu@aimrna.com; 916-412-9045

Growing Market Opportunity

- RNA based therapy is a validated approach with the approval of eight drugs by the FDA
- **Four ASO** drugs and **two siRNA** drugs approved by the FDA in recent years
- Eight RNA based COVID-19 vaccines in pre-clinical or phase 1 trials

GIVLAARI™ (givosiran) injection for subcutaneous use 189 mg/mL

MACUGEN® PEGAPTANIB SODIUM INJECTION

HEPLISAV-B® Hepatitis B Vaccine (Recombinant), Adjuvanted

VYONDYS 53 (golodirsen) Injection

DEFITELIO® (defibrotide sodium) injection 80 mg/mL

onpattro™ (patisiran) lipid complex injection

SPINRAZA® (nusinersen) injection 12 mg/5 mL

Tegsedi™ (inotersen) injection 284 mg/1.5 mL

EXONDYS 51™ (eteplirsen) Injection

KYNAMRO® (mipomersen sodium) injection 200mg/ml

AimRNA's Differentiated Solution & Benefits of Bioengineered RNAs

- Novel technology & streamlined platform to produce a wide variety of biologic RNA molecules including ncRNA , miRNAs, siRNAs, aptamers, ASOs, sRNAs, etc.
  - Larger yield / scale – tens milligrams of pure RNAs from 1 L of fermentation
  - Cost effective
- Biologic RNAs are more effective than synthetic counterparts
  - Folded & tolerated within living cells
  - Higher activity than synthetic counterparts
  - "Prodrug" strategy
- Enables in-house development of biologic RNA therapeutics to combat various diseases including lethal cancers

Benefits of Bioengineered RNAs

Biological RNAs (made in LIVING cells)

- Large scale (mg RNA/L culture)
- No/minimal natural modifications
- Variable lengths (e.g., 20-300 nt)
- Folded in living cells
- Tolerated by cells; safety needs more extensive studies
- More affordable with greatly reduced cost of goods

Synthetic RNAs (by chemical synthesis)

- Large scale (automated)
- ❑ Extensive chemical modifications
- ❑ Variable with desired short length (e.g., <60 nt)
- ❑ Under chemical environment; proper folding?
- ❑ Size, sequence and modifications affect safety
- ❑ Less affordable; expensive with increased size)

AIMRNA34 Reduces Tumor Burden in Lung Cancer Mouse Models

s.c. xenograft tumor model



Wang et al., JPET, 354:131 (2015)

Metastatic lung tumor model



Ho et al., JPET, 365:494 (2018)

AIMRNA34 Improves Overall Survival of Tumor Bearing Mice



Jian et al. Oncotarget (2017)

AIMRNA7 for the treatment of HCC



Jilek et al., MTNA (2019)

Team



Aiming Yu, Ph.D. – Founder & President

20+ years of experience in drug development, DM/PK/PD, miRNA research, and cancer therapy.

Neelu Batra, Ph.D. – Scientist

5+ years in cancer therapy and RNA bioengineering technology.



Meijuan Tu, Ph.D. – Scientist

9+ years experience in pharmaceutical sciences and 4+ years in RNA based cancer therapy.

Primo N. Lara, M.D. – Advisor

Physician Scientist – 25+ years of experience in clinical practice and research on new therapies.

Kit S. Lam, M.D., Ph.D. – Advisor

Physician Scientist – 38+ years of experience in anti-cancer drug development, drug delivery, imaging, etc.

IP & Regulatory Strategy

Intellectual Property	Regulatory
✓ Strong IP protection for RNA production platform technology and BERA drug candidates	✓ Production at the GMP facility at UC Davis
✓ Exclusive right to license patent from UC Davis	✓ Gathering GLP pharm/tox data ahead of pre-IND meeting with FDA

Raising $500,000 to fund IND-enabling studies

AimRNA's Emerging Pipeline



AimRNA

- **Novel RNA bioengineering platform technology**
- **One-of-a-kind biological RNA molecules**
- **Lead candidates for cancer therapy**

Aiming Yu, Founder & President
yu@aimrna.com; 916-412-9045